---
title: "Genmab Q1 FY26 operating profit slips to $180 million; revenue climbs 25% to $896 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285576452.md"
description: "Genmab reported a 25% increase in revenue to $896 million for Q1 FY26, while operating profit decreased to $180 million from $188 million. Royalty revenue rose 26% to $742 million, driven by higher sales of DARZALEX and Kesimpta. Costs of product sales increased by 55% to $65 million, primarily due to higher profit-sharing with AbbVie. Operating expenses, excluding acquisition charges, grew 25% to $606 million, reflecting investments in pipeline expansion. The FDA approved an sBLA for DLBCL, and Genmab maintained its 2026 financial guidance."
datetime: "2026-05-07T15:03:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285576452.md)
  - [en](https://longbridge.com/en/news/285576452.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285576452.md)
---

# Genmab Q1 FY26 operating profit slips to $180 million; revenue climbs 25% to $896 million

-   Genmab revenue climbed 25% to $896 million for the three months ended March 31, 2026, while operating profit slipped to $180 million from $188 million. \* Royalty revenue increased 26% to $742 million, driven by higher net sales of DARZALEX and Kesimpta. \* Cost of product sales rose 55% to $65 million, mainly on higher profit-sharing amounts payable to AbbVie related to EPKINLY sales. \* Operating expenses excluding acquisition and integration charges increased 25% to $606 million, reflecting pipeline expansion and continued investment in commercialization ahead of projected launches of Rina-S and petosemtamab. \* FDA approved an sBLA removing the recommendation for 24-hour hospitalization for patients with third line relapsed/refractory DLBCL; Genmab maintained 2026 financial guidance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071101PRIMZONEFULLFEED1001180659) on May 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [New York State Teachers Retirement System Sells 39,154 Shares of AbbVie Inc. $ABBV](https://longbridge.com/en/news/284797268.md)
- [AbbVie's SKYRIZI Secures Listing On Ontario And Alberta Formularies For UC Treatment](https://longbridge.com/en/news/285069224.md)
- [TG Therapeutics Q1 revenue rises, lifts 2026 outlook](https://longbridge.com/en/news/285364463.md)
- [Royalty Pharma Q1 adjusted EBITDA misses analyst estimates](https://longbridge.com/en/news/285365538.md)
- [BioRestorative reports Phase 2 BRTX-100 data showing 52% hit pain, function endpoint](https://longbridge.com/en/news/285584056.md)